RxDoctor Payments Data

Emily Waldron

Family · Watkinsville, GANPI 1144714775

Payments from drug & device makers

$1,605in general payments, 2019–2025

Across 89 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$207
  • Travere Therapeutics, Inc.$181
  • Amgen$162
  • Novartis$149
  • Bayer$138
  • Fresenius USA Marketing, Inc.$75
  • plus $693 from 18 others

What the payments were for

  • Food & beverage$1,58299%
  • Education$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,605 in reported general payments places this provider in the 75th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol22$18,318
LokelmaSodium Zirconium Cyclosilicate17$7,607
Calcitriol118$1,805
Hydralazine Hcl92$1,750
Potassium Chloride47$1,687
Torsemide70$1,241
Amlodipine Besylate153$780
Furosemide141$778
Lisinopril89$625
Losartan Potassium64$607
Nifedipine ErNifedipine23$571
Chlorthalidone45$452
Allopurinol39$328
Metoprolol Tartrate21$296
Atorvastatin Calcium42$282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$207$25,92539 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,258 family providers in Georgia.

Other family in Watkinsville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →